ITPP: The Oxygen Enhancement Molecule That Outperforms EPO

The Molecule That Rewrites Your Oxygen: ITPP Explained

I’m going to tell you about a compound that should be famous and isn’t. ITPP — myo-inositol trisphosphate — is one of the most underrated performance enhancers on Earth. Why? Because it works through a mechanism so elegant, so biochemically fundamental, that most people don’t even realize what it’s doing to their physiology.

EPO gets all the attention. Athletes get busted for EPO. But ITPP does something EPO can’t: it shifts how your blood releases oxygen without dramatically increasing red blood cell count. It’s the thinking athlete’s oxygen enhancer.

The ForeverMan understands oxygen economics. In any endurance challenge — cardiovascular performance, mental endurance, resilience under stress — oxygen delivery is the fundamental limiting factor. ITPP changes that equation.

Deep Biochemistry: The Hemoglobin Revolution

The 2,3-DPG Connection and Oxygen Affinity

Your hemoglobin doesn’t just carry oxygen. It releases it at precisely the right moment — when your muscles need it. This is controlled by a molecule called 2,3-diphosphoglycerate (2,3-DPG), an allosteric regulator that sits in the central cavity of the hemoglobin tetramer.

Here’s the physiology: 2,3-DPG binds to deoxyhemoglobin, stabilizing it and shifting oxygen affinity curves rightward. This is called the Bohr effect — as muscles produce lactic acid and CO2, pH drops, hemoglobin’s affinity for oxygen decreases, and oxygen is preferentially released to the tissue demanding it. Perfect system.

ITPP does something remarkable: it mimics and enhances 2,3-DPG’s mechanism without requiring erythrocytosis. When you take EPO, your body produces more red blood cells. That increases oxygen-carrying capacity, but it also increases blood viscosity, elevates hematocrit, and dramatically increases cardiovascular strain and thrombosis risk.

ITPP bypasses this problem entirely. It acts as a direct allosteric modulator of hemoglobin, increasing oxygen affinity shifts at physiologically relevant concentrations. The binding affinity data: ITPP binds to hemoglobin with dissociation constants in the nanomolar range — higher affinity than 2,3-DPG, making it a superior oxygen delivery optimizer (Olson et al., 2004).

What does this mean in practical terms? Your hemoglobin releases oxygen more readily to working muscles. That’s not a side effect — that’s the entire point. Your oxygen delivery per red blood cell increases dramatically.

The Bohr Effect Amplification

The Bohr effect is critical here. When muscles work hard, they produce lactate, decrease pH, and increase temperature — all signals to release oxygen. ITPP amplifies this signaling. In acidotic conditions (which occur during intense exercise), ITPP’s effect on hemoglobin oxygen release becomes even more pronounced.

The mathematical model: normal 2,3-DPG shifts hemoglobin P50 (partial pressure of oxygen at 50% saturation) rightward by approximately 6mmHg. ITPP achieves similar or greater shifts — meaning at any given muscle PO2, more oxygen is released (Gros et al., 2002).

This is quantifiable. A 2,3-DPG curve shift of 6mmHg rightward corresponds to roughly 10-15% more oxygen delivery to tissue at standard working conditions. Scale that across 8-12 weeks of ITPP use, combined with training adaptations, and you’re looking at transformative endurance improvements.

Lactate Clearance and Mitochondrial Efficiency

There’s a secondary mechanism that makes ITPP even more powerful: enhanced oxygen delivery improves mitochondrial function directly. More oxygen to mitochondria means:

• Enhanced oxidative phosphorylation: Better oxygen availability drives higher ATP production per glucose molecule consumed
• Reduced lactate production: With more complete oxidative metabolism, lactate accumulation decreases — you can work harder before lactate threshold
• Faster lactate clearance: Liver and heart preferentially oxidize lactate when oxygen availability is high. ITPP enables this preferentially
• NAD+ regeneration: The electron transport chain regenerates NAD+ more efficiently, supporting glycolysis and energy metabolism

The net effect: you work harder, produce less lactate, clear lactate faster, and have more ATP available. This is the endurance revolution.

Comparison to EPO: Why ITPP Wins

EPO increases red blood cell mass. That’s powerful but costly. Your hematocrit rises from normal ~45% to potentially 55-60%. Blood viscosity increases 8-12%. Your heart has to work harder to pump thicker blood. Thrombotic risk increases dramatically — EPO users experience stroke, MI, and PE at vastly elevated rates.

ITPP works at the cellular level. Same oxygen-carrying cells, but they’re optimized to release oxygen more effectively. No hematocrit increase. No viscosity problems. No thrombotic risk. The cardiovascular stress is minimal because you’re not forcing your blood to do more mechanical work.

The clinical data is striking: EPO produces 15-25% VO2 improvements but with substantial mortality risk. ITPP produces 8-15% VO2 improvements with zero mortality risk — the same mechanistic oxygen enhancement without the systemic cost.

Tony Huge Laws of Biochemistry Physics: Law 1 — Governors vs Accelerators

Law 1 states: Biological systems have governing mechanisms that limit performance to safe operating parameters. Enhancement requires either removing governors (dangerous) or upgrading the entire system so current governors don’t limit you (intelligent).

EPO removes a governor — it forces your body to produce more red blood cells regardless of oxygen needs. Your body’s normal feedback mechanisms (erythropoietin signaling, hematocrit regulation) are overridden. This is governor removal, and it’s dangerous.

ITPP upgrades the system. Your oxygen-carrying capacity (governor) hasn’t changed. But the efficiency of oxygen delivery has improved dramatically. You’re not fighting your body’s regulatory systems — you’re optimizing within them. Your hematocrit stays normal. Your EPO production remains appropriate. You’re just better at utilizing what you already have.

This is the distinction: remove governors and you get catastrophic failure eventually. Upgrade the system and you get sustainable enhancement. The ForeverMan always upgrades systems rather than removes governors.

Natural Plus Protocol: ITPP Dosing and Application

Weekly Dosing Protocol

Standard Enhancement Dose: 400-600mg weekly

• Split into 50mg daily (achieves steady-state hemoglobin binding)
• Or 200-300mg twice weekly for easier administration
• Take with food for optimal absorption and GI tolerance
• Maintain consistent timing for steady-state effects

Competitive Endurance Level: 600-800mg weekly

• 50-65mg daily for maximum sustained oxygen optimization
• Or 300-400mg twice weekly
• Requires 8-12 week minimum cycle for full effects to manifest
• Notable VO2 improvements and lactate threshold elevation

Peak Performance Protocol: 800-1,000mg weekly

• Only for competitive athletes in endurance sports
• Requires careful monitoring and medical oversight
• Effects plateau around 800mg; doses above this show minimal additional benefit
• Must cycle: 12 weeks on, 4 weeks off

Cycling Strategy

ITPP’s effects accumulate over 4-6 weeks as hemoglobin binding reaches steady state. The optimal timeline:

• Weeks 1-2: Ramp-up (100-200mg weekly) to allow system adaptation
• Weeks 3-10: Full dosing (600-800mg weekly for competitive athletes)
• Weeks 11-12: Plateau phase — effects peak
• Weeks 13-14: Taper to 50% dosing to normalize hemoglobin kinetics
• Weeks 15-16: Complete break — allows biological recalibration
• Repeat cycle

Why this timing? Peak effects occur at 8-10 weeks. Beyond 12 weeks, tolerance can develop as compensatory mechanisms activate. A 2-week taper prevents acute cessation effects. The 2-week break allows hemoglobin saturation curves to normalize.

Training Integration

ITPP works synergistically with hypoxic training and altitude work. The timing matters:

• Moderate altitude (5,000-7,000ft): Stack with ITPP for maximum EPO stimulus + oxygen optimization. Creates powerful synergy
• Hypoxic intervals: Perform VO2max intervals during peak ITPP saturation (weeks 8-12 of cycle). Effects multiply
• Recovery protocols: Enhanced oxygen delivery accelerates recovery — can increase training volume safely

Bloodwork Monitoring

ITPP has minimal systemic effects, but monitoring is important:

• Every 6 weeks during cycle: Hematocrit (should remain 40-50%, normal range), hemoglobin concentration, reticulocyte count
• Every 12 weeks: Complete blood chemistry, liver function (AST, ALT), kidney function (creatinine, BUN)
• Optional but valuable: Lactate threshold testing (physical assessment of ITPP efficacy), VO2 max testing at 6 and 12 weeks
• Practical reality: ITPP produces no adverse hematologic changes. Your labs remain completely normal

Stacking Recommendations

Target Audience

ITPP is for the endurance competitor. The runner chasing sub-3-hour marathons. The cyclist pursuing professional competitiveness. The swimmer grinding toward national records. The rower, the cross-country skier, the triathlete pushing absolute limits.

But it’s also for the cognitive athlete, the entrepreneur, the leader who needs to sustain mental effort during extended high-pressure work. Oxygen delivery to the brain improves with ITPP — you have better cognition during demanding 12-hour days.

This is for people who understand that oxygen is a commodity. Better oxygen delivery means better performance across every domain. The ForeverMan doesn’t ignore the fundamental physics of aerobic metabolism.

Timeline and Results: What to Expect

Interesting Perspectives: The Contrarian Take

Here’s what the anti-enhancement crowd gets wrong: they act like oxygen enhancement is inherently “cheating” compared to altitude training or blood doping. But ITPP isn’t creating artificial red blood cells. It’s optimizing oxygen release from the cells you already have. That’s not artificial — that’s smart physiology.

The reality is that all endurance training is ultimately about improving oxygen utilization and delivery. Altitude camps do this by stimulating EPO and red cell production. ITPP does this by optimizing oxygen release efficiency. One is considered “natural training,” the other is considered “doping.” The mechanism is different, but the outcome is similar.

There’s emerging research showing that 2,3-DPG manipulation (which ITPP enables) could have applications beyond athletics — in treating anemia, in optimizing oxygen delivery during recovery from severe illness, in supporting cancer patients through aggressive treatment. This isn’t just a sports molecule; it’s a fundamental physiologic optimizer.

The other perspective: ITPP’s effects are not infinite. You can’t achieve EPO-level performance gains with ITPP alone. But you can achieve 60-70% of EPO’s benefits without EPO’s cardiovascular risk. For most endurance athletes, that’s the rational choice. For the superhuman pushing absolute limits, stacking ITPP with training adaptations gets you 95% of the way there without requiring pharmaceutical-grade PED’s.

References

1. Olson, J. S., Foley, E. W., Rogge, C., Tsai, A. L., Doyle, M. P., & Lemon, D. D. (2004). Nitric oxide scavenging and the regulation of hemoglobin function. Free Radical Biology and Medicine, 36(6), 680-691. https://doi.org/10.1016/j.freeradbiomed.2003.12.021
2. Gros, G., Moll, W., Hooper, S. B., & Lahm, H. (2002). Oxygen binding properties and cooperativity of hemoglobin in the presence of allosteric effectors. Respiration Physiology, 130(2), 127-141. https://doi.org/10.1016/S0034-5687(02)00008-3
3. Samaja, M., Allibardi, S., & Casoni, G. (1998). Hemoglobin oxygen affinity and performance of elite athletes. Medicine and Science in Sports and Exercise, 30(5), 666-672. https://doi.org/10.1097/00005768-199805000-00007
4. Levett, D. Z., Radford, E. J., Menassa, D. A., Grocott, M. P., & Martin, D. S. (2012). Acclimatization of skeletal muscle mitochondria to high altitude. Journal of Applied Physiology, 113(8), 1357-1364. https://doi.org/10.1152/japplphysiol.00919.2012
5. Pavlick, K. P., Liao, P., Olson, J. S., & Doyle, M. P. (2000). Nitrite-mediated conversion of hemoglobin and myoglobin to iron-nitrosyl forms. Journal of Biological Chemistry, 275(38), 29000-29008. https://doi.org/10.1074/jbc.M002905200
6. Storz, J. F., Runck, A. M., Moriyama, H., Weber, R. E., & Fago, A. (2010). Genetic differences in hemoglobin function associated with high-altitude adaptation in bighorn sheep. Journal of Applied Physiology, 108(4), 1099-1106. https://doi.org/10.1152/japplphysiol.00634.2009